Dolby Laboratories, Inc. vs TransMedics Group Inc — how do they compare? Dolby Laboratories, Inc. trades at $60.6 (market cap $5.75B), while TransMedics Group Inc trades at $87.5 (market cap $3.10B). The key difference: Dolby Laboratories, Inc. is the larger of the two by market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| DLB | TMDX | |
|---|---|---|
Market Cap | $5.75B | $3.10B |
Sector | Industrials | Technology |
52-Week High | $75.62 | $150.42 |
52-Week Low | $48.51 | $61.99 |
Enterprise Value | $5.12B | $3.49B |
Dividend Yield | 2.35% | — |
Signals from Pluang's Aura AI — not financial advice
DLB trades at $60.90, down 1.93% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company has consistently beaten EPS estimates in recent quarters, including Q2 2026 with $0.69 actual versus $0.67 expected. Revenue has been stable around $1.3B annually, with a strong gross profit margin of 87.61% in 2025. Analyst consensus is a Buy with a price target of $87.50, suggesting significant upside. Recent news highlights growth in Dolby Atmos and automotive licensing.
The outlook for DLB is positive, supported by strong fundamentals and analyst optimism, but near-term execution risks and licensing volatility pose challenges. The stock's current valuation metrics, including a P/E of 26.11, appear reasonable given growth prospects. Key risks include revenue fluctuations and competitive pressures in the audio-video sector.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Trailing returns across standard periods
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →